NVAX · Novavax, Inc.

Protein-based COVID vaccine maker; post-pandemic revenue cliff, Sanofi licensing pivot

Risiko 8/10 · HIGH · revenue cliff · $7.37 ▼ 1.60%

Kennzahlen

• Price $7.37
• Market cap $1.2B
• P/E (ttm) n/a
• Div yield none
• 52-wk range $6.20 – $11.97

Wichtigste Risiken

• Post-COVID revenue collapse (Revenue) — EXTREME
• Dependence on Sanofi deal & milestones (Earnings) — HIGH
• Pipeline / clinical execution risk (Catalyst risk) — HIGH
• History of dilution & cash concerns (Shareholders) — HIGH

Fazit

A faded pandemic winner now reliant on partnerships and an unproven pipeline — binary and event-driven rather than a stable earnings story.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.